Abstract
Recent studies have demonstrated that pulmonary surfactant protein (SP)-A plays a potential role in modifying inflammation and immune function. To see whether SP-A could modify IL-8 production and release by eosinophils stimulated with ionomycin, SP-A purified from surfactant recovered from patients with alveolar proteinosis was added to eosinophils isolated by the negative-selection method with immunomagnetic beads, and cultured for 24 h. The concentrations of IL-8 in the cell-free supernatants and cell lysates were then measured by ELISA. SP-A attenuated the production of IL-8 by eosinophils in a concentration-dependent manner. SP-A also attenuated the release of IL-8 from the eosinophils. The addition of SP-A antibody (PE10) reversed these effects of SP-A completely. These data suggest that SP-A may have the potential to modify allergic inflammation by inhibiting the release and production of IL-8 by eosinophils.
MeSH terms
-
Antibodies, Monoclonal / pharmacology
-
Asthma / drug therapy
-
Asthma / etiology
-
Asthma / immunology
-
Dose-Response Relationship, Drug
-
Eosinophils / drug effects*
-
Eosinophils / immunology*
-
Humans
-
In Vitro Techniques
-
Inflammation / drug therapy
-
Inflammation / etiology
-
Inflammation / immunology
-
Interleukin-8 / biosynthesis*
-
Interleukin-8 / metabolism*
-
Ionomycin / pharmacology*
-
Lung / immunology
-
Lung / metabolism
-
Proteolipids / administration & dosage
-
Proteolipids / antagonists & inhibitors
-
Proteolipids / pharmacology*
-
Pulmonary Surfactant-Associated Protein A
-
Pulmonary Surfactant-Associated Proteins
-
Pulmonary Surfactants / administration & dosage
-
Pulmonary Surfactants / antagonists & inhibitors
-
Pulmonary Surfactants / pharmacology*
Substances
-
Antibodies, Monoclonal
-
Interleukin-8
-
Proteolipids
-
Pulmonary Surfactant-Associated Protein A
-
Pulmonary Surfactant-Associated Proteins
-
Pulmonary Surfactants
-
Ionomycin